2007
Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineered™ monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors
Goel S, Bauer R, Desai K, Bulgaru A, Iqbal T, Strachan B, Kim G, Kaubisch A, Vanhove G, Goldberg G, Mani S. Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineered™ monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors. Annals Of Oncology 2007, 18: 1704-1707. PMID: 17693421, DOI: 10.1093/annonc/mdm280.Peer-Reviewed Original ResearchConceptsING-1Human anti–human antibody (HAHA) responsesMonoclonal antibodiesGrade 3 pancreatitisAdvanced solid tumorsAdvanced refractory cancerPeak drug levelsRisk of pancreatitisAnti-tumor effectsStable diseaseMonotherapy studiesThird doseAntibody responseRefractory cancerMost adenocarcinomasDrug levelsPharmacokinetic samplesWeek 1Colon cancerPatientsSolid tumorsDrug accumulationCombination studiesFurther experienceSafety studies
2005
Phase I and pharmacokinetic study of a subcutaneously administered human-engineered monoclonal antibody ING-1 in patients with advanced adenocarcinomas
Kiner-Strachan B, Goel S, Vanhove G, Bauer R, Verdier-Pinard D, Karri S, Desai K, Bulgaru A, Macapinlac M, Mani S. Phase I and pharmacokinetic study of a subcutaneously administered human-engineered monoclonal antibody ING-1 in patients with advanced adenocarcinomas. Journal Of Clinical Oncology 2005, 23: 2558-2558. DOI: 10.1200/jco.2005.23.16_suppl.2558.Peer-Reviewed Original Research